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ABSTRACT
Objective: To investigate trends in incident and
prevalent diagnoses of type 2 diabetes mellitus (T2DM)
and its pharmacological treatment between 2000 and
2013.
Design: Analysis of longitudinal electronic health
records in The Health Improvement Network (THIN)
primary care database.
Setting: UK primary care.
Participants: In total, we examined 8 838 031
individuals aged 0–99 years.
Outcome measures: The incidence and prevalence of
T2DM between 2000 and 2013, and the effect of age,
sex and social deprivation on these measures were
examined. Changes in prescribing patterns of
antidiabetic therapy between 2000 and 2013 were also
investigated.
Results: Overall, 406 344 individuals had a diagnosis
of T2DM, of which 203 639 were newly diagnosed
between 2000 and 2013. The incidence of T2DM rose
from 3.69 per 1000 person-years at risk (PYAR) (95%
CI 3.58 to 3.81) in 2000 to 3.99 per 1000 PYAR (95%
CI 3.90 to 4.08) in 2013 among men; and from 3.06
per 1000 PYAR (95% CI 2.95 to 3.17) to 3.73 per 1000
PYAR (95% CI 3.65 to 3.82) among women. Prevalence
of T2DM more than doubled from 2.39% (95% CI 2.37
to 2.41) in 2000 to 5.32% (95% CI 5.30 to 5.34) in
2013. Being male, older, and from a more socially
deprived area was strongly associated with having
T2DM, (p<0.001). Prescribing changes over time
reflected emerging clinical guidance and novel
treatments. In 2013, metformin prescribing peaked at
83.6% (95% CI 83.4% to 83.8%), while sulfonylureas
prescribing reached a low of 41.4% (95% CI 41.1% to
41.7%). Both remained, however, the most commonly
used pharmacological treatments as first-line agents and
add-on therapy. Thiazolidinediones and incretin based
therapies (gliptins and GLP-1 analogues) were also
prescribed as alternate add-on therapy options, however
were rarely used for first-line treatment in T2DM.
Conclusions: Prevalent cases of T2DM more than
doubled between 2000 and 2013, while the number of
incident cases increased more steadily. Changes in
prescribing patterns observed may reflect the impact of
national policies and prescribing guidelines on UK
primary care.
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is an
increasing public health burden, and man-
aging the disease and its complications
accounts for close to 10% of the entire
National Health Service (NHS) budget in
the UK.1 T2DM was historically managed in
hospitals, but there has been a gradual shift
towards primary care. The NHS quality and
outcomes framework (QOF), introduced as
part of the general practitioner (GP) con-
tract in 2004, offers several ﬁnancial incen-
tives to encourage better monitoring and
management of several diseases in primary
care, including diabetes.2 Hence, primary
care data from the UK is increasingly being
used to study the disease and its
management.3 4
Signiﬁcant developments over the past
decade have inﬂuenced both the diagnosis
and pharmacological treatment of T2DM in
the UK. In 2000, for example, implementa-
tion of the revised WHO diabetes diagnostic
criteria led to a lower fasting plasma glucose
Strengths and limitations of this study
▪ This is, to the best of our knowledge, the first
study to examine both changes in rates of inci-
dent and prevalent diagnosis of type 2 diabetes
mellitus and antidiabetic prescribing patterns
using ‘real world’ UK primary care data between
2000 and 2013.
▪ This study does not contain data from secondary
care; however, type 2 diabetes mellitus is largely
managed in the primary care setting.
▪ Although several explanations for the factors that
might have triggered changes in prescribing pat-
terns of antidiabetic medications over time are
provided, there is no means of determining the
exact rationale behind prescribing decisions
without gathering more detailed information on
prescribing for each therapeutic category.
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threshold of 7.0 mmol/L being used for diagnosis rather
than 7.8 mmol/L.5 There has also been a greater aware-
ness of the need for aggressive treatment of T2DM to
reduce and delay long-term complications such as car-
diovascular and renal disease.6
Several new therapies have emerged in the past
decade, such as incretin-based therapies and SGLT-2
inhibitors, making the choice of suitable antidiabetic
regimens challenging.7 This may partly explain the
inertia in intensifying treatment for T2DM.8 Periodic
guidance from national and international bodies, such
as National Institute of Health and Care Excellence
(NICE), American Diabetes Association (ADA) and
European Association of Diabetics (EASD), in particular,
have offered more objective advice to prescribers.9 10
Our aim was to investigate how the incidence and
prevalence of T2DM diagnoses as well as prescribing pat-
terns have changed between 2000 and 2013 using data
from The Health Improvement Network (THIN)
primary care database.
METHODS
Data source
THIN is one of the largest databases to collect informa-
tion on patient demographics, disease diagnosis, man-
agement and prescribing from UK primary care. THIN
contains anonymised medical records from over 550
general practices throughout the UK, with around 12
million patients contributing data. It is reasonably repre-
sentative of the UK population.11 12 Information is col-
lected during routine patient consultations with GPs
from when a patient registers at a THIN afﬁliated
general practice. Symptoms and diagnosis of disease are
recorded using the Read code, hierarchical coding
system.13 14 THIN also provides information on referrals
made to secondary care and anonymised free text infor-
mation. A measure of social deprivation recorded as
quintiles of Townsend scores is also provided.15
Study population and period
All data included in this study was from practices which
met the acceptable mortality reporting (AMR) and
acceptable computer usage (ACU) standards. These are
measures of quality assurance for THIN data.16 17 The
AMR date is the date after which the practice is conﬁrmed
to have a rate of mortality sufﬁciently similar to that
expected for a practice with its demographic character-
istics, based on data from the Ofﬁce for National
Statistics.16 The ACU date is the date after which the prac-
tice is conﬁrmed to have on average at least one medical
record, one additional health record and two prescrip-
tions per patient per year.17 We included all individuals
aged 0–99 years who were registered with a general prac-
tice contributing data between 2000 and 2013.
The recording of diabetes diagnoses and management
in THIN is comprehensive and hence, there are several
ways an individual may be identiﬁed as diabetic. We
developed an algorithm to identify individuals with dia-
betes mellitus on whether they had at least two of the fol-
lowing records: (1) a diagnostic code for diabetes, (2)
supporting evidence of diabetes, for example, screening
for diabetic retinopathy or (3) treatment for diabetes.
The ﬁrst record of any of these three was considered as
the date of diagnosis. As some Read codes are non-
speciﬁc, we sought to distinguish patients with diabetes as
type 2 based on age at diagnosis, types of treatment and
timing of the diabetes diagnosis.18 For example, patients
with diabetes aged ≥35 years at time of diagnosis, on non-
insulin antidiabetic treatment or being managed without
treatment were classiﬁed as type 2. Patients with diabetes
diagnosed <35 years of age and on insulin were classiﬁed
as type 1. A sample of 500 complete electronic healthcare
records for individuals with diabetes were reviewed manu-
ally in THIN to assess if our clinical classiﬁcation algo-
rithm for diabetes type based on parameters above had
identiﬁed diabetes type correctly. In all 500 cases, manual
assignment of diabetes type based on clinical assessment
of the entire record and algorithmic assignment led to
equivalent classiﬁcation.
Definition of main outcomes
Incidence of T2DM
The date at which the ﬁrst recording of T2DM was made
was classiﬁed as the index date for diagnosis. Therefore,
our use of the term incidence with respect to T2DM in
this study refers to the ﬁrst record of T2DM to appear in
a patient’s electronic primary care record in the THIN
database. We excluded those who had their ﬁrst record-
ing of T2DM made within the ﬁrst 9 months of practice
registration as these were more likely to be prevalent
cases.19 We accounted for deaths and patients who had
left the practices in our denominator (follow-up time).
Prevalence of T2DM
For our analysis on prevalence of T2DM, we included as
our numerator all individuals who were ﬁrst recorded as
having T2DM within our study period and those
recorded as having T2DM from previous years. The
denominator included all individuals registered with a
general practice between 2000 and 2013. We accounted
for deaths and patients who had left the practices.
Prescription patterns analysis
The prevalence of use of different antidiabetic medi-
cines for T2DM was also compared across the time
period 2000–2013. We grouped antidiabetic medications
by therapeutic class into nine categories: metformin, sul-
fonylureas, insulins, thiazolidinediones, gliptins, GLP-1
analogues, SGLT-2 inhibitors, meglitinides and acarbose.
Prevalence of prescribed medications was calculated by
dividing the total number of individuals issued a pre-
scription for a particular antidiabetic medication class by
the total number of individuals issued any antidiabetic
medication in that calendar year.
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Patients with an incident recording of T2DM between
2000 and 2013 were analysed to examine how prescrib-
ing habits may have changed over time for newly diag-
nosed T2DM speciﬁcally. We determined what
antidiabetic drug was prescribed for initiating treatment
in T2DM, and then examined what antidiabetic agents
were typically added on by prescribers at a later stage
(when the disease had progressed further).
Statistical analyses
The overall crude incidence of T2DM was estimated per
1000 person years at risk (PYAR). This was determined by
totalling the number of patients with a ﬁrst recording of
T2DM between 2000 and 2013, and then dividing this
number by the total person years of follow-up for all
patient records for this period. We also determined crude
incidence rates by age, gender, social deprivation
(Townsend Score), and calendar year by restricting the
person years of follow-up to the respective category in
question. Person time was measured from the latest of:
the date of general practice registration plus 9 months or
1 January 2000 to the earliest of: date of ﬁrst recording of
T2DM, date of death, date patient left the practice, last
date of data collection from that practice or 31 December
2013. Multivariable Poisson regression analysis with (log)
person time as an offset was used to analyse changes in
incidence by age, gender, social deprivation and calendar
year while controlling for the other respective variables.
The overall crude prevalence of T2DM was calculated
by dividing the total number of patients with T2DM by
the total number of GP-registered patients between 2000
and 2013 accounting for deaths and patients who had
left the practices. Crude prevalence by age, gender,
social deprivation and calendar year was also deter-
mined. Multivariable Poisson regression analysis was used
to analyse changes in prevalence of T2DM and also the
effect of age, gender, social deprivation and calendar
year while controlling for the other respective variables.
To investigate the impact of clustering by practice,
multilevel random intercept models were compared to
all our standard Poisson models. Likelihood ratio tests
were used to explore the signiﬁcance of interaction
between variables.
Prescription records were also analysed to describe
changes over time in prescribing habits in primary care.
The percentage of patients with T2DM prescribed differ-
ent antidiabetic therapies for ever-use (prevalence), ﬁrst-
line use and as add-on therapy was determined for each
calendar year and the CIs were calculated.
Stata (Version 13.1) was used to conduct all analyses.
Ethics
THIN has been used for scientiﬁc research since
approval from the NHS South-East Multi-Centre
Research Ethics Committee in 2003. Scientiﬁc approval
to undertake this study was obtained from CMD Medical
Research’s Scientiﬁc Review Committee in February
2015. (SRC Reference Number: 15-011).
RESULTS
In total, 406 344 individuals with T2DM were identiﬁed
and among these, 203 639 were newly diagnosed
between 2000 and 2013.
Incidence of T2DM
The incidence of T2DM increased from 3.69 per 1000
PYAR (95% CI 3.58 to 3.81) in 2000 to 3.99 per 1000
PYAR (95% CI 3.90 to 4.08) in 2013 for men; and from
3.06 per 1000 PYAR (95% CI 2.95 to 3.17) to 3.73 per
1000 PYAR (95% CI 3.65 to 3.82) in 2013 for women
(table 1 and online supplementary appendix 1).
Incidence peaked in 2004 for both men and women:
4.80 per 1000 PYAR (95% CI 4.70 to 4.90) and 4.28 per
1000 PYAR (95% CI 4.19 to 4.38), respectively. There
was a signiﬁcant interaction between age and gender
(p<0.001); hence, all results are presented separately for
men and women in table 1. Women had a lower inci-
dence of T2DM than men (incidence rate ratios
(adjusted) 0.81 (95% CI 0.80 to 0.82) and individuals
from the most socially deprived areas had a signiﬁcantly
higher incidence than individuals from the least
deprived areas (Townsend Quintile 5 vs Townsend
Quintile 1; (IRR 1.57 95% CI 1.54 to 1.60) for men and
(IRR 1.92 95% CI 1.88 to 1.97) for women). In general,
incidence of T2DM increased with age, peaking between
70 and 79 years. Between ages 10 and 40 years, the inci-
dence of T2DM was higher among women. However,
after the age of 40 years, the crude incident rate became
higher among men though adjusted incidence rates
were similar.
Prevalence of T2DM
The prevalence of T2DM more than doubled from
2.39% (95% CI 2.37% to 2.41%) in 2000 to 5.32% (95%
CI 5.30% to 5.34%) in 2013 (table 2 and online
supplementary appendix 2). Prevalence was lower
among women (IRR 0.77, 95% CI 0.77 to 0.77) and
highest among individuals in the most deprived areas
(Townsend quintile 5 vs Townsend quintile 1; (IRR 1.75,
95% CI 1.74 to 1.75)). The prevalence increased with
age. The highest crude percentage of patients with
T2DM was seen in the 60–69 years age band: 37.65%
(95% CI 37.50% to 37.79%). However, the highest
adjusted prevalence was seen among the 70–79 years age
band (70–79 years age band vs 40–49 years age band
(IRR 5.95, 95% CI 5.92 to 5.97)) (table 2).
Prescribing in T2DM
Prevalence of antidiabetic medicine prescribed in patients
with T2DM
A total of 305 765 (75.2%) patients of 406 344 with
T2DM were prescribed antidiabetic medication. The
prescribing of metformin rose from 55.4% (95% CI
55.0% to 55.8%) in 2000 to 83.6% (95% CI 83.4% to
83.8%) in 2013, while the prescribing of sulfonylureas
decreased from 64.8% (95% CI 64.3% to 65.2%) in
2000 to 41.4% (95% CI 41.1% to 41.7%) of treated
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patients with T2DM by 2013 (ﬁgure 1 and online
supplementary appendix 3).
Prescribing of thiazolidinediones peaked in 2007 at
16.0% (95% CI 15.8% to 16.3%), while that of gliptins
peaked in 2013 at 15.4% (95% CI 15.2% to 15.7%) of
all treated patients (ﬁgure 1). Prescribing of acarbose
and meglitinides declined and were prescribed in <0.5%
of patients with T2DM on antidiabetic medications by
2013. Prescribing of insulin, however, remained stable
with 20–24% of treated patients being annually pre-
scribed insulin between 2000 and 2013.
Medicines used to initiate treatment in newly diagnosed
patients with T2DM
A total of 127 523 (62.6%) of 203 639 newly diagnosed
patients with T2DM were initiated on treatment between
2000 and 2013. In 2000, 51.1% (95% CI 49.2% to 53.0%)
were initiated on sulfonylureas and 45.1% (95% CI
43.2% to 47.1%) on metformin (ﬁgure 2 and online
supplementary appendix 4). Use of metformin as ﬁrst-
line therapy increased annually and by 2013, 91.0% (95%
CI 90.5% to 91.5%) of newly diagnosed T2DM patients
requiring treatment were being initiated on this therapy.
However, sulfonylureas usage as ﬁrst-line therapy
declined by 2013 to 6.3% (95% CI 5.9% to 6.8%). Few
patients with newly diagnosed T2DM were prescribed
insulin as ﬁrst-line therapy in 2013 1.7% (95% CI 1.4% to
1.9%).
Use of thiazolidinediones as ﬁrst-line therapy
remained low and peaked in 2004 (1.1% (95% CI 0.9%
to 1.3%)). Other antidiabetic therapies, such as gliptins,
GLP-1 analogues, acarbose or meglitinides, were used
very rarely as ﬁrst-line treatments (<1%) in any calendar
year.
Table 1 Incidence of type 2 diabetes mellitus by sociodemographic factors and year
Incidence of type 2 diabetes
Rate per 1000 PYAR (95% CI) Adjusted IRR (95% CI)*
Men Women Men Women
Overall 4.19 (4.17 to 4.21) 3.72 (3.70 to 3.74) 1 0.81 (0.80 to 0.82)
Age, years
0–9 0.04 (0.03 to 0.05) 0.04 (0.04 to 0.05) 0.01 (0.01 to 0.01) 0.01 (0.01 to 0.02)
10–19 0.11 (0.10 to 0.13) 0.28 (0.26 to 0.30) 0.03 (0.03 to 0.03) 0.09 (0.09 to 0.10)
20–29 0.36 (0.34 to 0.38) 1.15 (1.11 to 1.19) 0.09 (0.08 to 0.09) 0.37 (0.35 to 0.38)
30–39 1.36 (1.32 to 1.39) 1.91 (1.86 to 1.95) 0.33 (0.32 to 0.34) 0.63 (0.61 to 0.65)
40–49 4.02 (3.97 to 4.08) 3.00 (2.95 to 3.05) 1 1
50–59 7.86 (7.78 to 7.95) 5.43 (5.36 to 5.50) 1.98 (1.94 to 2.01) 1.83 (1.79 to 1.87)
60–69 11.87 (11.74 to 12.00) 8.48 (8.38 to 8.59) 2.98 (2.92 to 3.03) 2.84 (2.78 to 2.90)
70–79 12.68 (12.51 to 12.85) 10.32 (10.19 to 10.46) 3.18 (3.12 to 3.25) 3.43 (3.35 to 3.50)
80–89 9.08 (8.87 to 9.30) 8.00 (7.84 to 8.15) 2.26 (2.19 to 2.32) 2.57 (2.50 to 2.64)
90–99 5.96 (5.49 to 6.46) 4.55 (4.31 to 4.81) 1.48 (1.36 to 1.61) 1.45 (1.37 to 1.54)
Townsend quintile
1 3.86 (3.82 to 3.91) 2.99 (2.95 to 3.03) 1 1
2 4.19 (4.14 to 4.25) 3.50 (3.46 to 3.55) 1.09 (1.07 to 1.11) 1.15 (1.13 to 1.17)
3 4.29 (4.24 to 4.34) 3.86 (3.81 to 3.91) 1.25 (1.23 to 1.27) 1.37 (1.35 to 1.40)
4 4.47 (4.41 to 4.53) 4.32 (4.26 to 4.38) 1.42 (1.40 to 1.45) 1.63 (1.60 to 1.66)
5 4.62 (4.55 to 4.70) 4.75 (4.68 to 4.83) 1.57 (1.54 to 1.60) 1.92 (1.88 to 1.97)
Year
2000 3.69 (3.58 to 3.81) 3.06 (2.95 to 3.17) 1 1
2001 4.20 (4.08 to 4.31) 3.52 (3.42 to 3.63) 1.14 (1.09 to 1.19) 1.16 (1.10 to 1.21)
2002 4.48 (4.37 to 4.59) 3.73 (3.63 to 3.83) 1.22 (1.17 to 1.27) 1.24 (1.18 to 1.29)
2003 4.52 (4.41 to 4.62) 3.96 (3.87 to 4.06) 1.24 (1.19 to 1.29) 1.32 (1.27 to 1.38)
2004 4.80 (4.70 to 4.90) 4.28 (4.19 to 4.38) 1.32 (1.27 to 1.37) 1.44 (1.38 to 1.50)
2005 4.56 (4.46 to 4.66) 4.04 (3.95 to 4.13) 1.25 (1.20 to 1.30) 1.36 (1.30 to 1.42)
2006 4.52 (4.42 to 4.61) 3.93 (3.84 to 4.02) 1.24 (1.19 to 1.29) 1.33 (1.27 to 1.39)
2007 4.62 (4.52 to 4.72) 4.07 (3.98 to 4.16) 1.26 (1.22 to 1.31) 1.37 (1.32 to 1.43)
2008 4.62 (4.52 to 4.71) 4.06 (3.97 to 4.15) 1.26 (1.21 to 1.31) 1.37 (1.32 to 1.43)
2009 4.71 (4.61 to 4.80) 4.26 (4.18 to 4.36) 1.29 (1.24 to 1.34) 1.45 (1.39 to 1.51)
2010 4.48 (4.39 to 4.58) 4.10 (4.01 to 4.19) 1.23 (1.18 to 1.28) 1.40 (1.34 to 1.46)
2011 4.26 (4.17 to 4.35) 3.97 (3.88 to 4.05) 1.16 (1.12 to 1.21) 1.35 (1.30 to 1.41)
2012 4.40 (4.31 to 4.49) 4.00 (3.91 to 4.09) 1.20 (1.16 to 1.25) 1.37 (1.31 to 1.43)
2013 3.99 (3.90 to 4.08) 3.73 (3.65 to 3.82) 1.09 (1.05 to 1.13) 1.28 (1.22 to 1.33)
*Adjusted for other variables considered; age band, Townsend quintile, calendar year, respectively.
†Table 1 above is presented stratified by gender due to significant age-gender interaction (p<0.001).
‡For figure displaying data above, please consult online supplementary appendix 1.
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Medicines prescribed as add-on agents after initiation with
metformin in patients with newly diagnosed T2DM
Sulfonylureas were the most common add-on therapy
used in newly diagnosed patients with T2DM already
on metformin between 2000 and 2013; (ﬁgure 3 and
online supplementary appendix 5). However, sulfony-
lurea use as an add-on declined from 75.9% (95% CI
72.6% to 79.3%) in 2000 to 61.7% (95% CI 59.2% to
64.2%) in 2013. The use of thiazolidinedione as
add-on therapy to metformin peaked in 2002 at
26.9% (95% CI 25.0% to 28.8%), but the prescribing
then declined to 1.9% (95% CI 1.2% to 2.7%) by
2013.
Gliptins have become the second most common class
of antidiabetic medication added to metformin therapy,
with the use at 26.9% (95% CI 24.7% to 29.2%) in 2013.
Other antidiabetic therapies were less commonly added
on (ﬁgure 3).
Medicines prescribed as add-on agents after initiation with
sulfonylureas in patients with newly diagnosed T2DM
Metformin was the most common treatment added on
to newly diagnosed patients with T2DM on sulfonylureas
between 2000 and 2013; (ﬁgure 4 and online
supplementary appendix 6). In total, 89.8% (95% CI
87.7% to 92.0%) of patients diagnosed with T2DM in
2000 went on to have metformin add-on therapy after a
sulfonylurea, while 79.9% (95% CI 74.8% to 85.0%) had
metformin added on in 2013.
Insulins were the second most common add-on therapy
to sulfonylureas, accounting for 13.4% (95% CI 9.1% to
17.7%) of patients in 2013 (ﬁgure 4). Thiazolidinediones
and gliptins were the second and third most common
add-on therapies, respectively. Prescribing of meglitinides
remained <1% throughout, while GLP-1 analogues and
acarbose were used in <0.3% of patients as add-on medi-
cation in any given year.
DISCUSSION
The incidence of T2DM in UK primary care rose signiﬁ-
cantly between 2000 and 2005; thereafter, it stabilised
around 3.99 per 1000 PYAR in men and 3.73 per 1000
PYAR in women by 2013. Prevalence more than doubled
over the duration of the study to 5.3%. Men were 23%
more likely to have T2DM and those who were most
socially deprived were 75% more likely to have T2DM, as
compared to those least deprived. Individuals aged 70–
79 years had the highest adjusted prevalence of T2DM,
which was nearly six times higher than the reference age
band (40–49 years). Prescribing for T2DM also changed
considerably over the study, with metformin rising to
account for 91.0% of ﬁrst-line therapy among newly
diagnosed patients with T2DM and 79.9% of add-on
therapy for patients on sulfonylureas by 2013. Use of
gliptin therapy also increased and was used as an add-on
medicine in 26.9% of metformin-treated patients;
insulin rose to be used as an add-on treatment in 13.4%
of patients after a sulfonylurea by 2013.
The incidence of T2DM observed in this study is com-
parable to data that has been published previously.20 21
Previous studies were restricted to the period prior to
2010; however, our study includes data up to 2013. The
initial rise in diagnoses between 2000 and 2005, and the
plateau thereafter may be explained by the lowering of
plasma glucose threshold for diagnosis of diabetes in
2000.5 The increase in incidence observed in 2004 in
this study could also relate to the introduction of incen-
tivised payments in the UK as part of the quality and
outcomes framework for better monitoring of patients
with diabetes mellitus. Women were at greater risk of
Table 2 Prevalence of type 2 diabetes mellitus by
sociodemographic factors and year
Prevalence of type 2 diabetes
Percentage
prevalence (95% CI)
Adjusted IRR
(95% CI)*
Overall 4.62 (4.60 to 4.64)
Gender
Men 52.90 (52.75 to 53.05) 1
Woman 47.10 (46.95 to 47.25) 0.77 (0.77 to 0.77)
Age, years
0–9 0.09 (0.08 to 0.09) 0.01 (0.01 to 0.01)
10–19 0.41 (0.39 to 0.43) 0.03 (0.03 to 0.03)
20–29 2.19 (2.15 to 2.23) 0.12 (0.12 to 0.13)
30–39 6.54 (6.47 to 6.61) 0.38 (0.38 to 0.39)
40–49 15.18 (15.07 to 15.28) 1
50–59 27.30 (27.16 to 27.43) 2.28 (2.27 to 2.29)
60–69 37.65 (37.50 to 37.79) 4.13 (4.11 to 4.15)
70–79 36.75 (36.60 to 36.89) 5.95 (5.92 to 5.97)
80–89 22.18 (22.05 to 22.30) 5.59 (5.56 to 5.62)
90–99 4.85 (4.78 to 4.91) 4.00 (3.97 to 4.04)
Townsend quintile
1 20.23 (20.10 to 20.35) 1
2 19.80 (19.68 to 19.92) 1.12 (1.12 to 1.12)
3 20.74 (20.62 to 20.87) 1.32 (1.32 to 1.33)
4 19.90 (19.78 to 20.02) 1.53 (1.52 to 1.54)
5 14.95 (14.85 to 15.06) 1.75 (1.74 to 1.75)
Year
2000 2.39 (2.37 to 2.41) 1
2001 2.60 (2.58 to 2.62) 1.10 (1.08 to 1.11)
2002 2.84 (2.83 to 2.86) 1.20 (1.19 to 1.21)
2003 3.11 (3.09 to 3.13) 1.32 (1.30 to 1.33)
2004 3.40 (3.38 to 3.42) 1.44 (1.43 to 1.45)
2005 3.66 (3.64 to 3.67) 1.55 (1.53 to 1.56)
2006 3.88 (3.86 to 3.90) 1.64 (1.63 to 1.65)
2007 4.10 (4.08 to 4.12) 1.73 (1.71 to 1.74)
2008 4.33 (4.32 to 4.35) 1.82 (1.81 to 1.84)
2009 4.56 (4.54 to 4.58) 1.91 (1.90 to 1.93)
2010 4.78 (4.76 to 4.80) 2.01 (1.99 to 2.02)
2011 4.98 (4.96 to 5.00) 2.08 (2.07 to 2.10)
2012 5.17 (5.15 to 5.19) 2.16 (2.14 to 2.18)
2013 5.32 (5.30 to 5.34) 2.21 (2.19 to 2.23)
*Adjusted for other variables considered; gender, age band,
Townsend quintile, calendar year, respectively.
†For figure displaying data above, please consult online
supplementary appendix 2.
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developing T2DM relative to men between the ages of
10 and 40 years, in keeping with other published work;21
after this age, rates increased more signiﬁcantly in men.
Individuals from the most socially deprived areas in our
study were at greatest risk of developing the disease.
This is of concern as a study in the US has shown a
strong association between socioeconomic status and
diabetes-related mortality.22
The rise in prevalence of T2DM described in this
study was similar to that reported by Diabetes UK and
the International Diabetes Federation in 2013.23–25
Prevalence rates of T2DM observed in this study in the
UK are similar to what has been observed in other
European countries, such as Denmark and Sweden, but
lower than that observed in Germany and the US, par-
ticularly for the recent years.26 27
Similar studies on prescribing conducted with smaller
cohorts in the US have shown medication choices to be
quite different. For example, in a US cohort study of
data between 2009 and 2013 (n=15 516), 57.8% of
Figure 1 Prevalence of
prescribing of different anti-
diabetic medications among all
patients with type 2 diabetes on
treatment.
*Other=Sum of prevalence of
Acarbose, GLP-1 analogues,
Meglitinides and SGLT-2 inhibitors.
**For detailed values of point
estimates and CIs, please consult
online supplementary appendix 3.
Figure 2 Prevalence of
prescribing of different anti-
diabetic medications used to
initiate treatment in newly
diagnosed patients with type 2
diabetes.
*Other=Sum of prevalence of Insulins,
Thiazolidinediones, Gliptins,
Acarbose, GLP-1 analogues,
Meglitinides and SGLT-2 inhibitors.
**For detailed values of point
estimates and CIs, please consult
online supplementary appendix 4.
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patients with T2DM initiated therapy with metformin,
23.0% with sulfonylurea, 13.1% with gliptins and 6.1%
with thiazolidinediones,28 while the corresponding per-
centages in our study (n=57 518) for the same period
2009–2013 were 90.0%, 7.6%, 0.4% and 0.1%, respect-
ively. This signiﬁcant selection of metformin over other
therapies in the UK suggests an adherence, particularly
for treatment initiation, to cost-effective care as pub-
lished via periodic updates by NICE. This reliance on
metformin for ﬁrst-line therapy has also been evident in
other studies conducted in Germany and Denmark, in
particular.29 30
Metformin use increased steadily from 2000 and was
prescribed to 91% of newly diagnosed patients with
T2DM requiring treatment in 2013. In 2000, metformin
was recommended by NICE for ﬁrst-line use in obese
patients with T2DM only, while non-obese patients were
still being recommended sulfonylureas and insulins.31
However, by 2005, metformin was the recommended
ﬁrst-line treatment choice by all bodies as it is well toler-
ated,9 10 does not induce weight gain or hypoglycaemia,
and was the only diabetic treatment found to have a
long-term beneﬁt in reducing cardiovascular risks and
organ damage.6 10
Figure 3 Prevalence of
prescribing of different anti-
diabetic medications as add-on
therapy in patients with type 2
diabetes on metformin.
*Other=Sum of prevalence of Insulins,
Acarbose, GLP-1 analogues,
Meglitinides and SGLT-2 inhibitors.
**For detailed figures on point
estimates and CIs, please consult
online supplementary appendix 5.
Figure 4 Prevalence of
prescribing of different anti-
diabetic medications as add-on
therapy in patients with type 2
diabetes on sulfonylureas.
*Other=Sum of prevalence of
Acarbose, GLP-1 analogues,
Meglitinides and SGLT-2 inhibitors.
**For detailed figures on point
estimates and CIs, please consult
online supplementary appendix 6.
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We found that the use of sulfonylureas as a ﬁrst-line
agent declined among newly diagnosed patients with
T2DM, in keeping with published clinical guidance.9 10
This decline may also be explained by the availability of
more treatment options, the risk of weight gain and
hypoglycaemia attributed to this class of drugs; and
because these were shown not to reduce long-term com-
plications of diabetes.32 33 Nevertheless, 61.7% of
patients with T2DM diagnosed in 2013 still had sulfony-
lureas added to their metformin treatment.
We observed a decline in thiazolidinedione prescrib-
ing after 2003 in response to an increasing awareness of
adverse effects of these drugs, such as cardiotoxicity,
highlighted in safety alerts for rosiglitazone by regulatory
agencies in 2007.34 Additionally, risks of weight gain,
fractures and bladder cancer still exist among currently
licensed thiazolidinediones, which may explain their
limited use despite evident efﬁcacy.35
Since their emergence in 2006, gliptins have rarely
been used as ﬁrst-line therapy in newly diagnosed
patients with T2DM. However, their usage as add-on
therapy has risen rapidly, perhaps, as they do not induce
weight gain or hypoglycaemia.36 Further increase in
gliptin use may depend on data emerging on their long-
term beneﬁts for microvascular and macrovascular
complications.37
GLP-1 analogues were the ﬁrst antidiabetic treatments
to become available that could induce weight loss;
however, we have shown that their prescribing in UK
primary care particularly as add-on therapy after metfor-
min remains low (1.1%). This is in considerable contrast
to prescribing in Denmark where a study examining
data for a similar period (2000–2012) provided evidence
that nearly 7% of patients with T2DM on metformin
had GLP-1 therapy added on.29 Lower use in the UK
may be explained by the publication of the NICE
appraisal of the GLP-1 analogue, liraglutide, in 2010
that recommended use of these drugs only in those
patients who were already on two other therapies, had
high BMIs or were contraindicated to at least three
other antidiabetic medications.38
A small percentage of newly diagnosed patients with
T2DM (1.7%) are still being initiated on insulin and a
growing number are having insulin prescribed as add-on
therapy. Though current guidance does not support
early introduction of insulin, some studies have demon-
strated a beneﬁt.39
Meglitinides were used in less than 2% of patients
annually, between 2000 and 2013. These drugs require
multiple daily dosing, carry a risk of inducing hypogly-
caemias, and are more costly than sulfonylureas.9 Use of
acarbose has also continued to fall, perhaps as NICE
restrict their recommendation to use in patients who
cannot tolerate other oral agents.40 SGLT-2 inhibitors
have been the latest class of antidiabetic therapy to
emerge; hence, overall prescribing was low (0.5% in
2013). These have been recommended by NICE as
add-on treatment, and can aid with weight loss and
blood pressure control. They do, however, carry an
increased risk of genitourinary tract infections and long-
term beneﬁts are unknown.41 42
Strengths and limitations of this study
This is the ﬁrst study, to the best of our knowledge, to
detail changes in recording of diagnoses as well as pre-
scribing for T2DM using UK primary care data between
2000 and 2013. We have also provided insight into
factors that may have driven these changes.
Furthermore, THIN has been shown to be broadly rep-
resentative of the UK population and a particularly suit-
able database for drug utilisation work.11 There are,
however, certain limitations to highlight. Though our
algorithm for identiﬁcation of patients with T2DM uti-
lised several variables in addition to diagnostic codes,
such as treatment and time of diagnosis, there still
remains a risk of some misclassiﬁcation of T2DM. Also,
this study did not measure prescribing of antidiabetic
medicines in secondary care. However, it is well estab-
lished that the majority of prescribing for T2DM is in
primary care.43 We also did not examine prescribing pat-
terns in important clinical subgroups, such as patients
with chronic kidney disease, which should be addressed
in future work. Prescribing of a medication does not, of
course, equate to adherence to therapy. However, the
purpose of this study was to examine recording of diag-
nosis and physician prescribing choices only. Variation
in dosages or between drugs within the same thera-
peutic class were not considered. Some of this has been
explored previously.8
CONCLUSION
There has been a signiﬁcant increase in the number of
incident and prevalent cases of T2DM between 2000
and 2013. Though the incidence of T2DM has some-
what plateaued since 2005, the prevalence has contin-
ued to rise suggesting that patients with T2DM are being
diagnosed younger and live longer. Being male, older,
and from a more socially deprived area were factors all
strongly associated with having T2DM.
Prescribing patterns reﬂected clinical guidance from
NICE, in particular. Metformin emerged as the most
widely prescribed agent though sulfonylureas, despite
their limitations, remained the second most common
therapy prescribed. Latest international guidelines,
which may be reﬂected in future NICE updates, encour-
age greater use of the broader armamentarium now
available for T2DM. We may, therefore, begin to see
more varied, patient-speciﬁc prescribing. With these and
further developments in practice anticipated, it will be
important to review in the next few years how prescrib-
ing patterns in primary care for T2DM have further
changed.
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